NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program utilizes the Antibody Radio-Conjugate (ARC), lintuzumab-Ac-225 for hematologic indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM). Actinium recently completed its Phase 2 Actimab-A trial in patients newly diagnosed with AML who are over the age of 60 and unfit for intensive chemotherapy. Dr. Gary Schiller Professor Medicine, Hematology-Oncology at UCLA Medical Center and Dr. Tapan Kadia, Assistant Professor of Medicine, Department of Leukemia at the MD Anderson Cancer Center will highlight Actinium's post Phase 2 trial development plans for Actimab-A in AML.
Actinium is also developing Actimab-MDS, which is intended to be a single dose, chemotherapy-sparing targeted conditioning agent for patients with high-risk MDS. Currently, this patient population either cannot undergo a bone marrow transplant or have poor outcomes. Management will provide an update on the regulatory pathway for Actimab-MDS following positive interactions with the U.S. Food and Drug Administration (FDA).
Dr. Mark Berger, Actinium's Chief Medical Officer said, "Our CD33 program has progressed significantly in 2018 resulting in a highly valuable body of data that we are using to inform our ongoing development strategy. Our Antibody Radio-Conjugate approach, given its differentiated mechanism of action, has allowed us to expand this program beyond a traditional AML directed approach which is where other CD33 programs in the industry are focused. The unique ability of our ARC's enable cell killing to occur not just via internalization of the antigen but also from the cell surface and by crossfire. In addition, our ARCs labeled with radioactive actinium are characterized by the high linear energy transfer of alpha radiation which is able to cause double stranded DNA breaks via a single alpha particle hit. This potent cell killing power of alpha radiation when used in an efficiently targeted manner as in our Actimab program enables us to expand into other radio-sensitive CD33 expressing malignancies such as multiple myeloma and now for targeted conditioning for MDS, both of which are indications where Actinium is developing the only CD33 targeting agent. In addition, we have moved into a novel combination trial for patients with significant unmet need with our Actimab-A CLAG-M study. We are pleased to have made this progress, but we believe the next evolution of our CD33 program will be even more exciting. As such, we look forward to highlighting our post Phase 2 trial development plans for Actimab-A with Dr. Schiller and Dr. Kadia."
Sandesh Seth, Actinium's Chairman and Chief Executive Officer said, "We are excited to introduce these latest initiatives as they clearly establish Actinium's Antibody Radio-Conjugate based CD33 program as the industry leader. Further, we are about to enter a period that will showcase data from several of the CD33 program initiatives that this team has advanced. Given the inherent nature of our technology, the expertise of our team and strong relationships with thought leaders, we have been able to craft a development strategy that leverages the strengths of our drug candidates and Antibody Warhead Enabling technology platform into indications with high unmet medical needs. The webinar will showcase the attractiveness of using our Antibody Radiation-Conjugate approach in meeting these needs. In addition, it will establish the strategic importance of Actimab-MDS in enabling our company to develop a multi-asset pipeline of targeted conditioning agents which have the potential to improve access and outcomes for patients undergoing bone marrow transplant and cellular therapy in a chemotherapy-free or chemotherapy-sparing manner."
Conference call and webcast Participation Information
Date: Friday, October 26, 2018
Time: 11:00 AM ET
Webcast Registration: https://onecast.thinkpragmatic.com/ses/9DnzzB5lR-DnSV3zQJ1LDQ~~
U.S. Participant Dial-in: (718) 865-8336
U.S./Canada Toll Free Dial-in: (855) 427-0225
Conference ID: 4831
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC's or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium's pipeline of clinical-stage targeted conditioning ARCs target the antigens CD45 and CD33 for patients with a broad range of hematologic malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma and Non-Hodgkin's lymphoma. Actinium's Iomab-ACT program is designed to be a universal lymphodepletion technology intended to eliminate the need for chemotherapy-based conditioning prior to CAR-T or other adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product candidate, is currently enrolling patients in the pivotal Phase 3 SIERRA trial in patients age 55 or older, with active, relapsed or refractory AML. Iodine-131-apamistamab (Iomab-B), combines the anti-CD45 monoclonal antibody labeled with iodine-131 for myeloablation prior to a bone marrow transplant. CD45 is expressed on leukemia, lymphoma and normal immune cells. Iomab-B has been studied in over 500 patients in 10 clinical trials in numerous hematologic diseases. Actinium's Iomab-ACT program is an expansion of its CD45 program that is intended to be a universal, chemotherapy-free solution for targeted lymphodepletion prior to CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is expected to improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment and potentially other adoptive cell therapies. Due to its lower payload dose, lymphodepletion with the Iomab-ACT program can be accomplished through a single outpatient infusion. Actinium intends to advance its Iomab-ACT program with CAR-T focused collaborators from academia and industry.
Actinium's pipeline also includes a potentially best-in-class CD33 program with its ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in multiple Phase 2 and Phase 1 clinical trials for targeting conditioning and as a therapeutic in multiple diseases and indications including AML, MDS and MM. Actinium applies its CD33 program at high doses to target CD33+ cells of the myeloid lineage in combination with reduced intensity conditioning (RIC), which together are intended to result in myeloablative outcomes with a more benign and well tolerated profile than high intensity chemotherapy myeloablation. Actinium is focused on applying its CD33 program at low doses in combination with other therapeutic modalities including chemotherapy, targeted agents and immunotherapies.
Actinium is also developing its proprietary AWE or Antibody Warhead Enabling technology platform which utilizes radioisotopes including iodine-131 and the highly differentiated actinium-225 coupled with antibodies to target a variety of antigens that are expressed in hematological and solid tumor cancers. The AWE technology enables Actinium's internal pipeline and with the radioisotope Actinium-225 is being utilized in a collaborative research partnership with Astellas Pharma, Inc. Actinium's clinical programs and AWE technology platform are covered by a portfolio of 77 patents covering composition of matter, formulations, methods of use and also methods of manufacturing the radioisotope Actinium-225 in a cyclotron.
More information is available at www.actiniumpharma.com and our Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Actinium Pharmaceuticals, Inc.
Principal Financial Officer
Rx Communications Group
View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-webinar-showcasing-actimab-a-post-phase-2-trial-plans-and-actimab-mds-regulatory-update-300734989.html
SOURCE Actinium Pharmaceuticals, Inc.